| abstract |
The use of melagatran or a pharmaceutically acceptable salt, solvate or compound of the formula ** (See formula) ** wherein Cgl represents cyclohexylglynyl, Aze represents acetidine-2-carboxyl, Pab represents 4-amidinobenzylamino, R1 represents C1-6 alkyl linear or branched and the OH group replaces one of the amidino hydrogens in Pab, for the manufacture of a medicament for use in cholesterol lowering therapy. |